Five Hours Of Pain Relief? Preclinical Study Shows Promising Results With This Non-Toxic CBD
Portfolio Pulse from Jelena Martinovic
MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) announced positive results from a preclinical study of its investigational cannabinoid Supera-CBD, which showed potential in alleviating acute inflammatory pain. The study found that Supera-CBD targeted and reduced inflammatory pain within 60 minutes, providing relief for up to five hours. The U.S. Department of Justice Drug Enforcement Administration (DEA) concluded that Supera-CBD will not be considered a controlled substance or listed chemical under the Controlled Substances Act (CSA). Following the announcement, MyMD Pharmaceuticals’ shares traded 4.4139% higher at $0.44 per share.
October 19, 2023 | 4:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MyMD Pharmaceuticals' Supera-CBD showed promising results in a preclinical study, potentially alleviating acute inflammatory pain. The DEA concluded that Supera-CBD will not be considered a controlled substance. Following the news, MyMD's shares traded 4.4139% higher.
The positive results from the preclinical study of Supera-CBD, along with the DEA's conclusion that it will not be considered a controlled substance, are likely to boost investor confidence in MyMD Pharmaceuticals. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100